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Abstract
Background: Heart failure is a common complication of diabetes characterized by an eleva-
tion in left ventricular filling pressures (LVF) that often develops in the absence of clinical 
symptoms. Diastolic dysfunction in the setting of low total testosterone (LTT) occurs through 
changes in the regulation of peripheral hemodynamics. LTT is highly prevalent among indi-
viduals with type 2 diabetes. The aim of this study was to compare LVF in male diabetic pa-
tients with no structural heart disease and normal serum testosterone levels vs. those with LTT.
Methods: Type 2 diabetic patients were assessed using tissue Doppler imaging to evalu-
ate LVF and other conventional parameters of diastolic function. The E/e’ ratio was used to 
estimate LVF through the ratio of peak passive trans-mitral left ventricular inflow velocity to 
the peak passive inflow velocity at the lateral mitral annulus. Patients were assigned to one of 
two groups based upon their total testosterone levels. Group A consisted of low (< 3.5 ng/mL) 
testosterone levels and group B consisted of normal (> 3.5 ng/mL) testosterone levels.
Results: A total of 148 male patients were included: group A — 47 (32%) patients; group B — 
101 (68%) patients, respectively. Mean age was 58 ± 5.8 years and mean time of diabetes evo-
lution was 7 ± 3.1 years. There were no significant differences between the groups regarding 
age, duration of diabetes evolution, hypertension, weight, heart rate, body mass index, and echo-
cardiographic parameters. The E/e’ ratio for group A was 8.05 ± 1.9 vs. 6.1 ± 1.7 for group B  
(p < 0.0001). The E/A ratio was 0.94 ± 0.10 vs. 1.19 ± 0.12 (p = 0.01), deceleration time 
242 ± 7.4 ms vs. 205 ± 9 ms (p = 0.026) and systolic pulmonary artery pressure 27 ±  
± 2.2 mm Hg vs. 22 ± 1.7 mm Hg (p = 0.11).
Conclusions: Patients with type 2 diabetes and LTT have a higher E/e’ ratio demonstrating  
a pre-clinical increase in LVF when compared to similar patients with normal testosterone 
levels. This finding is independent of time of diabetes evolution, hypertension and other echo-
cardiographic parameters. (Cardiol J 2015; 22, 2: 206–211)
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Introduction
Hypogonadotropic hypogonadism is character-
ized by low plasma concentrations of testosterone 
as well as inappropriately low levels of luteinizing 
hormone (LH) and follicle stimulating hormone 
(FSH). The prevalence of hypogonadotropic hy-
pogonadism in male patients with type 2 diabetes 
is high, affecting nearly 30% of individuals. In 
contrast, this condition is relatively uncommon 
in type 1 diabetes [1, 2]. Heart failure (HF) is 
another frequent complication of diabetes that 
occurs through a variety of mechanisms. Current 
evidence indicates that myocardial damage in 
diabetic patients affects diastolic function before 
systolic function [3]. Patients who develop HF in 
the setting of diastolic dysfunction have increased 
left ventricular filling pressures (LVF) that can oc-
cur years before symptom onset and even in the 
absence of apparent structural heart disease.
In recent years, a large body of literature 
has emerged suggesting a link between andro-
gen deficiency and cardiovascular disease [4–6]. 
Testosterone deficiency has been shown to be an 
independent risk factor for poor outcomes in HF 
patients. Furthermore, it has also been identified 
as an independent marker of reduced exercise 
capacity in HF [7, 8]. Testosterone is thought to 
influence diastolic function through its impact on 
peripheral hemodynamics [9].
Pulsed tissue Doppler imaging (TDI) has 
been validated as a reliable index of LVF, using 
the E/e’ ratio [10]. In this parameter, the ratio of 
early peak trans-mitral inflow velocity (E) to early 
peak velocity at the lateral mitral annulus (e’) is 
calculated. The E/e’ ratio is used to detect and 
follow the progression of diastolic dysfunction in 
asymptomatic diabetic patients [11]. In spite of 
this, the influence of testosterone on LVF in these 
patients remains uncertain.
The aim of this study was to compare LVF 
in male diabetic patients with no structural heart 
disease and normal testosterone levels to those 
with low total testosterone (LTT).
Methods
Patient population
In total, 148 male patients in the age of 20 and 
65 years old (58 ± 5.8 years) with type 2 diabetes 
were included. Type 2 diabetes was diagnosed in 
accordance with The Expert Committee on the Di-
agnosis and Classification of Diabetes Mellitus [12]. 
Patients were excluded if they had been castrated 
as treatment for testicular or prostate cancer or if 
they were taking any medications known to affect 
sex hormone concentrations. Patients had no prior 
history of cardiovascular disease (myocardial infarc-
tion, ischemic stroke), HF, cardiovascular symptoms 
(dyspnea, orthopnea, paroxysmal nocturnal dyspnea, 
and angina pectoris) or asymptomatic cardiomyopa-
thy. Arrhythmias (atrial fibrillation, frequent ectopic 
ventricular or supraventricular beats) or diastolic 
dysfunction (E/e’ > 15) resulted in exclusion from 
the study. Echocardiographic abnormalities such 
as left ventricular hypertrophy or valvular heart 
disease also resulted in exclusion from the study. 
Questionnaires were given to determine the du-
ration of diabetes evolution as well as medical 
treatment undertaken for diabetes, hypertension 
and dyslipidemia. Body mass index (BMI), blood 
pressure and heart rate were measured at the time 
of echocardiography.
Study design
Prospective observational study of consecu-
tive patients with type 2 diabetes recruited be-
tween September 2010 and November 2012.
Patients were assigned to one of two groups 
depending upon total serum testosterone levels. 
Patients with total serum testosterone levels below 
3.5 ng/mL were assigned to group A while patients 
with levels greater that 3.5 ng/mL were assigned 
to group B, based on a previously published con-
sensus statement from the International Society 
of Andrology, European Association of Andrology 
and the American Society of Andrology that defined 
the cut-off value to consider hypogonadism [13].
Testosterone assessment was always con-
ducted between 7 AM and 10 AM. Venous blood 
samples were taken: serum samples were ob-
tained by centrifugation and immediately frozen 
for further analysis. Total testosterone level was 
measured by quimioluminiscence (ng-mL). In all 
patients, FSH, LH and prolactin was measured in 
order to rule out hypothalamic pituitary gonadal 
axis disease. Patients provided written consents 
to participate in the study.
Echocardiography
Imaging was performed using General Electric 
Vivid 7® (GE Health care, Chalfont St. Giles, United 
Kingdom) operated by an expert ultrasonographer 
who was blinded to patient testosterone levels. 
Chamber dimensions were evaluated using stand-
ard procedures, including left ventricle (LV) mass 
index [14] and left atrial (LA) volume index [15]. 
Mitral and pulmonary venous Doppler flow veloci-
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ties were recorded in the apical 4-chamber view 
as previously described [16]. Mitral inflow meas-
urements included peak early (E) and peak late (A) 
flow velocities, the E/A ratio, the deceleration 
time (DT) of early mitral flow velocity, and the 
isovolumic relaxation time (IVRT). Assessment 
of LVF was performed using TDI to calculate the 
E/e’ ratio. The parameter was obtained by meas-
uring the peak trans-mitral LV inflow velocity (E) 
and the peak velocity at the lateral mitral annulus 
during passive filling (e’). The ratio was calculated 
as an average of 3 consecutive measurements; and 
both groups were compared. Adequate mitral and 
TDI signals were recorded in all patients, whereas 
pulmonary venous flow signals were suitable for 
analysis in only 55% of the cases. That was the rea-
son because we did not include pulmonary venous 
flow results in the final analysis.
Statistical analysis
Data were analyzed using Stata 12 software 
(College Station, Texas USA). Descriptive statis-
tics are presented as mean ± standard deviation 
for continuous data and relative frequencies for 
categorical variables. Data were analyzed using 
the Mann-Whitney U test and c2. Relationships 
between the serum testosterone concentration and 
E/e’ ratio, age, glycemic control, and other vari-
ables were examined by linear regression analysis. 
Multiple regression analysis was performed to 
assess the combined influence of variables on the 
mean E/e’ ratio. To examine the effects of various 
factors on mean E/e’ ratio the following factors 
were considered independent variables: BMI, sys-
tolic blood pressure, total cholesterol and glycated 
hemoglobin (HbA1c). Statistical significance was 
defined as a p value < 0.05.
Results
The clinical characteristics of the population 
are described in Table 1. Mean age was 58 ± 5.8 
years; duration of diabetes evolution was 7 ± 
± 3.1 years. HbA1c was 6.9 ± 0.6%, and BMI was 
30.1 ± 3 kg/m2. The prevalence of hypertension 
was 65%. There were no significant differences 
between the LTT and normal testosterone groups. 
The mean value of total testosterone was 2.9 ± 
± 0.54 ng/mL in group A and 5.1 ± 1.31 ng/mL 
in group B (p < 0.001) (Table 2). Medical therapy 
for diabetes, hypertension and dyslipidemia did 
not differ significantly between the groups (Fig. 1).
The E/e’ ratio for group A was 8.05 ± 1.9 vs. 
6.1 ± 1.7 for group B; p < 0.0001 (Fig. 2). Other 
parameters of LV filling as E/A ratio (0.94 ± 0.10 
vs. 1.19 ± 0.12, p = 0.01), and DT (242 ± 7.4 ms 
vs. 205 ± 9 ms (p = 0.026) showed significant dif-
ferences between groups. The systolic pulmonary 
artery pressures did not differ between groups. 
Group A had a 6-fold increased risk of an E/e’ ratio 
> 5 (group A = 91.67% vs. group B = 64.56%; odds 
ratio = 6.04; confidence interval = 1.69–21.47; 
p = 0.005). Differences remained significant after 
adjustment for age, duration of diabetes evolution, 
BMI, lipids, HbA1c and drug treatment. Multiple 
regression analyses did not demonstrate any rela-
tionship between E/e’ and medical treatment, the 
presence of hypertension, or other cardiovascular 
risk factors.
Discussion
The prevalence of type 2 diabetes has in-
creased dramatically over the past two decades. 
This has been mirrored by a corresponding in-
crease in the rates of obesity and sedentary life 
style [17]. Cardiovascular disease is the primary 
cause of morbidity and mortality in these patients, 
with numerous studies identifying a strong associa-
tion between diabetes and the development of LV 
structural abnormalities. This process is independ-
ent of other relevant covariates such as BMI and 
increased arterial pressure [18]. Even in the pres-
ence of normal chamber anatomic characteristics, 
diabetes has been found to negatively affect systolic 
mechanics and diastolic filling [19]. Clearly, the 
development of HF in diabetic patients is common 
and frequently associated with a poor prognosis. 
Table 1. Characteristics of the population (n = 148).
Age [years] 58 ± 5.8
Duration of diabetes [years] 7 ± 3.1
Glycated hemoglobin (HbA1c) [%] 6.9 ± 0.6
Body mass index [kg/m2] 30.1 ± 3
Total testosterone [ng/mL] 4.66 ± 1.65
Hypertension 65.5%
Low density lipoprotein [mg/dL] 119.3 ± 23
High density lipoprotein [mg/dL] 39.9 ± 7
Glucose fasting [mg/dL] 133 ± 28.9
Heart rate [bpm] 68 ± 5.8
Left atrial volume [mm3] 50.1 ± 14 
Septal thickness [mm] 9.5 ± 1.3 
Ejection fraction [%] 61 ± 2.2
Left ventricular mass index [g/m2] 80 ± 11
Left atrial volume index [mL/m2] 17.9 ± 1.3
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In a prospective study by From et al. [20], it was 
found that for every 1.0 increment in the E/e’ ratio, 
the hazard ratio of developing HF increased by 
3% in asymptomatic diabetic patients. This study 
highlights the importance of LVF as a prognostic 
risk factor for the development of HF even in the 
absence of clinical symptoms. In addition to this, 
diabetics have a significantly higher prevalence of 
Table 2. Baseline clinical, biochemical and echocardiographic characteristics of groups with low 
(group A) and normal (group B) testosterone levels.
Characteristics Group A (n = 47) Group B (n = 101) P
Age [years] 58 ± 7.01 59 ± 5.8 NS
Duration of diabetes [years] 6 ± 3.19 7 ± 3.06 0.21
Weight [kg] 88 ± 13.77 90 ± 9.8 0.45
Height [cm] 174 ± 0.06 173 ± 0.05 NS
Body mass index [kg/m2] 29.05 ± 3.86 29.84 ± 2.86 NS
Heart rate [bpm] 64.5 ± 9,65 70.5 ± 8.42 0.089
Triglicerydes [mg/dL] 130 ± 74.02 124 ± 27.86 0.098
Low density lipoprotein [mg/dL] 118 ± 24.46 127 ± 23.16 0.17
High density lipoprotein [mg/dL] 41 ± 8.29 37 ± 6.77 0.06
Glycated hemoglobin (HbA1c) [%] 6.9 ± 1.04 7.05 ± 0.58 0.41
Fasting glycemia [mg/dL] 132 ± 28.32 133 ± 14.52 NS
Total testosterone [ng/mL] 2.9 ± 0.54 5.1 ± 1.31 0.001
E [m/s] 0.80 ± 0.16 0.73 ± 0.12 0.160
A [m/s] 0.85 ± 0.14 0.61 ± 0.13 0.001
E/A 0.94 ± 0.10 1.19± 0.12 0.01
Deceleration time [m/s] 242 ± 7.4 205 ± 9 0.026
E/e’ ratio 8.05 ± 1.9 6.1 ± 1.78 0.001
Systolic pulmonary artery pressure [mm Hg] 27 ± 2.2 22 ± 1.7 0.11
Left ventricular ejection fraction [%] 61.5 ± 3.24 60.5 ± 4.24 NS
Left ventricular diastolic diameter [mm] 47 ± 1.5 46 ± 4.20 NS
Septal thickness [mm] 9.5 ± 2.3 9.4 ± 2.1 NS
Left atrial volume index [mL/m2] 18.3 ± 1.9 17.7 ± 1.5 NS
Left ventricular mass index [g/m2] 81 ± 9 79 ± 13 NS
Figure 1. Medical treatment; ACEI — angiotensin converting enzyme inhibitors; CCB — calcium channel blockers.
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hypogonadism than individuals without diabetes 
[21]. The high incidence of LTT in male patients 
with type 2 diabetes is thought to be the result of 
a complex interaction between multiple endocrine 
processes. High rates of peripheral conversion of 
testosterone to estrogen occur through increased 
aromatase activity in the setting of hyperinsuline-
mia and elevated inflammatory cytokines. This 
process is further exacerbated by visceral obesity. 
Hyperinsulinemia and increased cytokine levels 
also lead to a decreased release of gonadotropin 
releasing hormone (GnRH) and LH by the central 
nervous system. This ultimately results in the 
inhibition of Leydig cell’s function and decreased 
testosterone production [22].
Testosterone has been found to influence car-
diovascular physiology through a variety of mecha-
nisms. Current evidence indicate that testosterone 
may have both direct genomic and non-genomic 
effects on the vascular wall [23]. Additionally, it 
has been shown to act as a peripheral vasodilator 
by affecting intracellular calcium regulation and 
has the potential to increase cardiac output [24]. 
Some studies have demonstrated that androgen 
action is mediated by direct calcium antagonism in 
the vascular smooth muscle [25]. Testosterone is 
a powerful antagonist of L-type voltage-operated 
Ca2+ channels (LVOCCs). This blockade of LVOCCs 
induces vasorelaxation of both vascular and non-
vascular smooth muscle; ultimately resulting 
in vasodilation of small arteries, independent of 
the type of endothelium [26, 27]. These findings 
highlight the direct role of testosterone levels on 
peripheral hemodynamics.
Our findings suggest that male patients with 
type 2 diabetes and LTT have higher LVF than 
those with normal testosterone levels and worst 
parameters of diastolic function like E/A ratio and 
DT. This holds true in patients with a long diabetes 
evolution, good metabolic control (HbA1c), and the 
absence of myocardial disease or symptoms (Fig. 3). 
TDI indices were used as they correlate well with 
intra-cardiac ventricular pressure tracings in dia-
betic patients. We did not find significant differences 
between groups regarding LA volume index and pul-
monary pressures (markers of advanced diastolic dys-
function disease) probably by analyzing a population 
without manifestations of structural heart disease.
To the best of our knowledge, there are no 
other studies that evaluated the influence of tes-
tosterone on LVF. Our study identified no rela-
tionship between the E/e´ ratio and the presence 
of hypertension, medical therapy for diabetes, or 
different drug therapies that can influence vascular 
resistance and diastolic function. The influence of 
testosterone on peripheral hemodynamics should 
be investigated in a larger cohort of patients.
Despite advances in evidence-based pharma-
cological therapies, HF patients continue to exhibit 
significant morbidity and mortality with rates of up 
to 30% at 1 year [28]. Various studies suggest an 
important role for pre-clinical interventions and 
close follow-up of patients at risk for the develop-
ment of HF [29]. In this study, long-term follow-up 
of patients with type 2 diabetes and LTT will be 
necessary to determine whether or not LTT will 
ultimately influence the development of clinical 
diastolic dysfunction and clinical HF. The results of 
the present study confirm the hypothesis that LTT 
could be an early marker for the development of 
diastolic dysfunction in male patients with diabetes.
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Figure 2. Differences between groups in E/e’ ratio.
Figure 3. Correlation between total testosterone and 
E/e’ ratio.
Limitations of the study
We carefully excluded all patients with history 
of coronary disease and angina or equivalent symp-
toms and those with positive stress test for ischemia 
in the last year. However, we did not perform stress 
test in all patients before being included in the study. 
Future research should also consider how silent 
ischemia could influence the results.
Conclusions
Male patients with type 2 diabetes and low 
testosterone levels have higher LV filling pressure 
than controls with normal testosterone levels. This 
finding may help detect patients at higher risk of 
HF development.
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